Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment

• Status: Unknown status
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the relationship between the side effects of valproate sodium in the treatment of epilepsy in Han Chinese and the genetic polymorphisms of drug metabolizing enzymes and pharmacokinetics of valproate sodium.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: First Affiliated Hospital, Sun Yat-Sen University
• Treatments: Anticonvulsants; Valproic Acid

Criteria

Inclusion Criteria:

• The patients must have been diagnosed as epilepsy according to The International League Against Epilepsy (ILAE) criteria published in 2001.

• The patients must sign the informed consent. And for the patients who are under 18 years old, both the signatures of their legal guardians and that of the patients are required on the written informed consent.

• The patients are receiving the regimen of 15-30mg/kg valproate sodium given as daily oral administration.

Exclusion Criteria:

• Pregnant women, women in breast-feeding period and the women who refuse to take contraception measures during treatment.

• Patients with poor compliance.

• Patients who have blood transfusion during the therapy.